Abiopharma

🔍 JOHNSON DAVID EDWARD (Director)

Company: Liquidia Corp (LQDA)

Report Date: 2026-06-16

Detailed Transactions and Holdings:

• Acquired 5,882 shares of Common Stock, $0.001 par value per share ("Common Stock") (Direct)
  Date: 2026-06-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,882.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-16 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 8,157,347.00 | Footnotes: F4

Footnotes:

• F1: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis.
• F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.
• F3: David Johnson ("Mr. Johnson") is deemed to hold the securities reported herein for the benefit of certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds and Accounts.
• F4: Securities held by the Caligan Funds and Accounts to which Caligan serves as investment manager and related entities. Mr. Johnson (together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
• REMARKS: Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Caligan may be deemed to be a director by deputization of the Issuer by virtue of the fact that Mr. Johnson currently serves on the Issuer's board of directors.